{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"PR (partial remission)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"HI (hematologic improvement)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"SD (stable disease)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"PD (progressive disease)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Response to treatment was assessed after two cycles, according to International Working Group (IWG) criteria.","groups":[{"description":"BEX and GM-CSF were administered in 4 week cycles. BEX was given orally with food daily for 28 days at the FDA-approved dose for treatment of CTCL of 300 mg/m2 and GM-CSF was given at a daily dose of 125 µg/m2 subcutaneously for 28 days.","id":"OG000","title":"Bexarotene + GM-CSF"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"assessed after 2 cycles, up to 2 years","title":"Clinical Response (Complete and Partial)","type":"PRIMARY","unitOfMeasure":"Participants"}